Study drug TQB3909 for CLL/SLL that keeps coming back
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old, and able to give informed consent
- Your health status should be good (ECOG 0–1) and you should be expected to live more than 3 months
- You must have CLL or SLL diagnosed using the 2018 guideline criteria
- If you have SLL, scans (CT or MRI) must show measurable spots
- If you can become pregnant, you must use birth control during the study and for 6 months after, and take a pregnancy test within 7 days before starting
- You must be willing to follow study rules and attend visits as scheduled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This trial tests a new pill called TQB3909 that may offer another option for patients with CLL/SLL who have tried other treatments. It is considered for patients whose cancer has relapsed or not responded to prior therapies, or who could not tolerate them.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.